We read with interest Gordon and Yaffe’s letter about our article, “Women’s Acceptance of Overdetection in Breast Cancer Screening: Can We Assess Harm-Benefit Tradeoffs?” We agree with them on some points but disagree on several others.
Australia is one of the first high-income countries to implement primary human papillomavirus (HPV)-based screening, ahead of the USA, UK, Canada and New Zealand. Primary HPV testing has recently become one of the recommended options for cervical screening in the USA, but patients may need [...]
This study aimed to evaluate Australian web-based resources that provide information about the changes to the cervical screening program.
This paper set out to assess different strategies for communicating to older adults about stopping cancer screening. We found that older adults may reduce their screening intention without reporting increased cancer anxiety when clinicians use a more confronting strategy communicating they may not live long [...]
Profound changes were made to the Australian National Cervical Screening Program in December 2017, which included a reduction in the frequency of screening and a new cervical screening test. To explore the attitudes and experiences of health professionals practising in Australia since implementation of these [...]
This paper sought to explore women’s experiences of the renewed National Cervical Screening Program in Australia from the perspective of women who have received different human papillomavirus (HPV) test results. Women aged 25 to 74 are now screened every 5 years with primary HPV screening.
We believe that it is imperative to have robust evidence about whether to communicate breast density information to women and, if so, how best to do it. Before this happens, there first needs to be an assessment of the balance between the benefits and harms [...]
The use of more medicalised labels can increase both concern about illness and the desire for more invasive treatment. This study analyses the media’s coverage of an Analysis article in The BMJ which generated a large amount of high-profile international media coverage. It aims to understand how [...]
In the article below, University of Sydney Public Health Professor Alexandra Barratt explores the contention around the AgeX trial, the biggest randomised trial ever, which is considering how long should older women continue to be screened for breast cancer. It is published as part of [...]
This paper investigates the change in mammography screening technology, comparing digital mammography with the older film-screen mammography. Findings suggest that the transition to the newer technology has not resulted in health benefits for screened women.